FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144367322> ?p ?o ?g. }

• W2144367322 endingPage "313" @default.
• W2144367322 startingPage "308" @default.
• W2144367322 abstract "We report on a multicenter phase II trial of (90)yttrium-ibritumomab-tiuxetan ((90)YIT) as first-line stand-alone therapy for patients with follicular lymphoma (FL).Fifty-nine patients with CD20(+) FL grade 1 to 3a in stages II, III, or IV, age 50 years old or older requiring therapy were enrolled. They received (90)YIT according to standard procedure. If complete response (CR) or unconfirmed complete response (CRu) without evidence for minimal residual disease (MRD) 6 months after application of (90)YIT was achieved, patients were observed without further intervention. The same applied to patients with partial response (PR) or with stable disease (SD). Patients with CR but with persisting MRD were to receive a consolidation treatment with rituximab. Primary end point was the clinical and molecular response rate. Secondary end points were time to progression, safety, and tolerability.Six months after treatment with (90)YIT, 56% of the patients showed a CR or CRu and 31% achieved a PR. After a median follow-up of 30.6 months, the progression-free survival (PFS) was 26 months. There was a trend for shorter PFS in patients with increased lactate dehydrogenase (LDH). Of the 26 patients who had CR 12 months after (90)YIT, only three had relapsed. Median time to next treatment has not been reached. The most common toxicities were transient thrombocytopenia and leukocytopenia. Nonhematologic toxicities never exceeded grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE v2.0).(90)YIT is well tolerated and achieves high response rates. Patients with increased LDH tend to relapse earlier, and individuals in remission 1 year after (90)YIT appear to have long- lasting responses." @default.
• W2144367322 created "2016-06-24" @default.
• W2144367322 creator A5005310278 @default.
• W2144367322 creator A5011863718 @default.
• W2144367322 creator A5013330370 @default.
• W2144367322 creator A5013866174 @default.
• W2144367322 creator A5023107894 @default.
• W2144367322 creator A5023254633 @default.
• W2144367322 creator A5024386803 @default.
• W2144367322 creator A5028510513 @default.
• W2144367322 creator A5028913166 @default.
• W2144367322 creator A5035277761 @default.
• W2144367322 creator A5038506100 @default.
• W2144367322 creator A5061903335 @default.
• W2144367322 creator A5067716137 @default.
• W2144367322 creator A5077919557 @default.
• W2144367322 creator A5089152448 @default.
• W2144367322 date "2013-01-20" @default.
• W2144367322 modified "2023-10-18" @default.
• W2144367322 title "⁹⁰Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial" @default.
• W2144367322 cites W1912693401 @default.
• W2144367322 cites W1980152924 @default.
• W2144367322 cites W2014654561 @default.
• W2144367322 cites W2020094108 @default.
• W2144367322 cites W2037797717 @default.
• W2144367322 cites W2093620219 @default.
• W2144367322 cites W2101648653 @default.
• W2144367322 cites W2110646221 @default.
• W2144367322 cites W2113228924 @default.
• W2144367322 cites W2114233385 @default.
• W2144367322 cites W2116402582 @default.
• W2144367322 cites W2118513494 @default.
• W2144367322 cites W2132443196 @default.
• W2144367322 cites W2138404218 @default.
• W2144367322 cites W2152996672 @default.
• W2144367322 cites W2154643481 @default.
• W2144367322 cites W2156522119 @default.
• W2144367322 cites W2169578616 @default.
• W2144367322 cites W2267583049 @default.
• W2144367322 cites W4293203547 @default.
• W2144367322 doi "https://doi.org/10.1200/jco.2011.41.1553" @default.
• W2144367322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23233718" @default.
• W2144367322 hasPublicationYear "2013" @default.
• W2144367322 type Work @default.
• W2144367322 sameAs 2144367322 @default.
• W2144367322 citedByCount "102" @default.
• W2144367322 countsByYear W21443673222013 @default.
• W2144367322 countsByYear W21443673222014 @default.
• W2144367322 countsByYear W21443673222015 @default.
• W2144367322 countsByYear W21443673222016 @default.
• W2144367322 countsByYear W21443673222017 @default.
• W2144367322 countsByYear W21443673222018 @default.
• W2144367322 countsByYear W21443673222019 @default.
• W2144367322 countsByYear W21443673222020 @default.
• W2144367322 countsByYear W21443673222021 @default.
• W2144367322 countsByYear W21443673222022 @default.
• W2144367322 countsByYear W21443673222023 @default.
• W2144367322 crossrefType "journal-article" @default.
• W2144367322 hasAuthorship W2144367322A5005310278 @default.
• W2144367322 hasAuthorship W2144367322A5011863718 @default.
• W2144367322 hasAuthorship W2144367322A5013330370 @default.
• W2144367322 hasAuthorship W2144367322A5013866174 @default.
• W2144367322 hasAuthorship W2144367322A5023107894 @default.
• W2144367322 hasAuthorship W2144367322A5023254633 @default.
• W2144367322 hasAuthorship W2144367322A5024386803 @default.
• W2144367322 hasAuthorship W2144367322A5028510513 @default.
• W2144367322 hasAuthorship W2144367322A5028913166 @default.
• W2144367322 hasAuthorship W2144367322A5035277761 @default.
• W2144367322 hasAuthorship W2144367322A5038506100 @default.
• W2144367322 hasAuthorship W2144367322A5061903335 @default.
• W2144367322 hasAuthorship W2144367322A5067716137 @default.
• W2144367322 hasAuthorship W2144367322A5077919557 @default.
• W2144367322 hasAuthorship W2144367322A5089152448 @default.
• W2144367322 hasConcept C126322002 @default.
• W2144367322 hasConcept C141071460 @default.
• W2144367322 hasConcept C197934379 @default.
• W2144367322 hasConcept C203092338 @default.
• W2144367322 hasConcept C2776694085 @default.
• W2144367322 hasConcept C2777058707 @default.
• W2144367322 hasConcept C2777063308 @default.
• W2144367322 hasConcept C2778375690 @default.
• W2144367322 hasConcept C2779338263 @default.
• W2144367322 hasConcept C2780653079 @default.
• W2144367322 hasConcept C2909463153 @default.
• W2144367322 hasConcept C535046627 @default.
• W2144367322 hasConcept C71924100 @default.
• W2144367322 hasConcept C90924648 @default.
• W2144367322 hasConceptScore W2144367322C126322002 @default.
• W2144367322 hasConceptScore W2144367322C141071460 @default.
• W2144367322 hasConceptScore W2144367322C197934379 @default.
• W2144367322 hasConceptScore W2144367322C203092338 @default.
• W2144367322 hasConceptScore W2144367322C2776694085 @default.
• W2144367322 hasConceptScore W2144367322C2777058707 @default.
• W2144367322 hasConceptScore W2144367322C2777063308 @default.
• W2144367322 hasConceptScore W2144367322C2778375690 @default.
• W2144367322 hasConceptScore W2144367322C2779338263 @default.
• W2144367322 hasConceptScore W2144367322C2780653079 @default.
• W2144367322 hasConceptScore W2144367322C2909463153 @default.

• next